期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 82, 期 4, 页码 427-434出版社
WILEY
DOI: 10.1038/sj.clpt.6100319
关键词
-
Scientific support about the concept of using molecular data for risk stratification and tailoring health-care interventions to the individual -a strategy broadly defined as molecular medicine ( MM) -is accumulating. Molecular-based health-care technologies are beginning to enter clinical practice, but their use has revealed many scientific, economic, and organizational barriers to the effective delivery of targeted health care. We conducted a qualitative interview study to describe the MM landscape, with an emphasis on eliciting policy recommendations for the field from a broad range of stakeholders in MM and health care. Molecular medicine has widespread support but will require changes in how molecular-based technologies are evaluated, how health care is financed and delivered, and how clinicians and consumers are trained and prepared for its use. In particular, researchers and developers need to become active participants in a variety of clinical integration strategies to realize the promise of MM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据